AGORACOM Small Cap CEO Interviews

Novamind (NM: CSE) Is Building the Infrastructure Required for a Regulated Psychedelics Industry

Listen Later

The global behavioural health market size is expected to reach approximately US$ 245 billion by 2027 and  estimated to grow at CAGR of 2.5 % over the forecast time frame 2020 to  2027.

As a consequence of the increasing incidence of mental health  disorders, global demand for mental health facilities is increasing.

Psychedelics are going to go through parabolic, paradigm-shifting  growth because of their ability to treat anxiety and depression amongst  other things

Novamind is a leading mental health company specialized in  psychedelic medicine, building the infrastructure required for a  regulated psychedelics industry.

Highlights:

  • Rapidly expanding a network of outpatient mental health clinics and research sites
  • 4 clinics in Utah, 1 more anticipated this quarter
  • Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
    • Ketamine treatment volume grew 90% from 2019 to 2020
    During the same period, total Spravato™ treatments rose 400%
  • Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
  • Building centers of excellence for future approved psychedelic treatments
  • Approximately CAN$1,900,000 in 2019 revenue
  • Strong insider ownership (32.3%)
    • ...more
    View all episodesView all episodes
    Download on the App Store
    AGORACOM Small Cap CEO InterviewsBy AGORACOM
    • 5
    • 5
    • 5
    • 5
    • 5

    5

    1 ratings